NEOSENT: Early Anti-PD-1 Therapy In High-Risk Stage II Melanoma
NCT07680699
·
clinicaltrials.gov ↗
RECRUITING
Status
250
Enrollment
OTHER
Sponsor class
Conditions
Cutaneous Melanoma
Interventions
OTHER:
Anti-PD1 Therapy Timing
Sponsor
AC Camargo Cancer Center